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Abstract
Pheochromocytomas (PHEOs) and paragangliomas (PGLs) related to mutations in the mitochondrial succinate
dehydrogenase (SDH) subunits A, B, C, and D, SDH complex assembly factor 2, and the von Hippel-Lindau
(VHL) genes share a pseudohypoxic expression profile. However, genotype-specific differences in expression have
been emerging. Development of effective new therapies for distinctive manifestations, e.g., a high rate of malig-
nancy in SDHB- or predisposition to multifocal PGLs in SDHD patients, mandates improved stratification. To iden-
tify mutation/location-related characteristics among pseudohypoxic PHEOs/PGLs, we used comprehensive
microarray profiling (SDHB: n = 18, SDHD-abdominal/thoracic (AT): n = 6, SDHD-head/neck (HN): n = 8, VHL:
n = 13). To avoid location-specific bias, typical adrenal medulla genes were derived from matched normal medul-
las and cortices (n = 8) for data normalization. Unsupervised analysis identified two dominant clusters, separating
SDHB and SDHD-AT PHEOs/PGLs (cluster A) from VHL PHEOs and SDHD-HN PGLs (cluster B). Supervised anal-
ysis yielded 6937 highly predictive genes (misclassification error rate of 0.175). Enrichment analysis revealed that
energy metabolism and inflammation/fibrosis-related genes were most pronouncedly changed in clusters A and B,
respectively. A minimum subset of 40 classifiers was validated by quantitative real-time polymerase chain reaction
(quantitative real-time polymerase chain reaction vs.microarray: r= 0.87). Expression of several individual classifiers
was identified as characteristic for VHL and SDHD-HN PHEOs and PGLs. In the present study, we show for the first
time that SDHD-HN PGLs share more features with VHL PHEOs than with SDHD-AT PGLs. The presented data sug-
gest novel subclassification of pseudohypoxic PHEOs/PGLs and implies cluster-specific pathogenic mechanisms and
treatment strategies.
Neoplasia (2013) 15, 435–447
Introduction
Predispositions to certain tumors have been linked to an ever-increasing
number of mutations. To date, mutations in 11 different genes have
been associated with development of paragangliomas (PGLs), which
are catecholamine-producing, chromaffin cell tumors, including adre-
nal pheochromocytomas (PHEOs). Initially, discovery of mutations
was guided by syndromic presentation and family history; however,
more recently discovered mutations can present in seemingly sporadic
fashion. Known PHEO/PGL susceptibility genes are von Hippel-
Lindau (VHL) and neurofibromatosis 1 (NF1) in the homonymous syn-
dromes (VHL and NF1, respectively), RET proto-oncogene in multiple
endocrine neoplasia type 2, succinate dehydrogenase D (SDHD) in fa-
milial PGL type 1 (PGL1) and Carney-Stratakis Syndrome (CSS),
SDHC in PGL3 and CSS, SDHB in PGL4 and CSS, SDH complex
assembly factor 2 (SDHAF2) in PGL2, prolyl hydroxylase 2 (PHD2/
EGLN1), transmembrane protein 127 (TMEM127 ), kinesin family
member 1B, SDHA, andMYC-associated factor X (reviewed in [1]). Most
recently, activating mutations in hypoxia-inducible factor 2α (HIF2α)
have been associated with PGL and polycythemia [2].
Notwithstanding the multitude of susceptibility genes, mutation-
derived PHEOs/PGLs separate into merely two main clusters, one
containing SDHA, SDHB, SDHC, SDHD, SDHAF2, and VHL and
the other consisting of NF1, RET proto-oncogene, TMEM127, kinesin
family member 1B, and MYC-associated factor X mutation–derived
PHEOs/PGLs (reviewed in [1,3]). The PHEOs/PGLs of the first
mentioned cluster are characterized by a pseudohypoxic phenotype, i.e.,
inappropriate stabilization of HIFα subunits under normoxia (reviewed
in [1,3]).
Under normoxia, hydroxylation of HIFα by PHDs (PHD1/
EGLN2, PHD2/EGLN1, and PHD3/EGLN3) designates them for
VHL-dependent ubiquitylation and subsequent degradation [4].
Accordingly, VHL mutations can promote HIFα stabilization. Simi-
larly, SDH dysfunction causes HIF stabilization by succinate or reactive
oxygen species accumulation-mediated PHD inhibition [5,6].
Despite increasing evidence for differences within the pseudo-
hypoxic cluster [7–9], the molecular basis for distinct clinical behaviors
including the preferential site of tumor development, biochemical pheno-
type, or metastatic potential remains largely unknown. Mutations in
SDHB have been associated with extra-adrenal PGLs and high risk of
malignancy [1,3]. SDHDmutations, however, predispose to multifocal
PHEOs/PGLs, primarily from the head and neck (HN) region, with
low metastatic risk [3]. However, HN PGL can be inoperable, or sur-
gery can lead to severe side effects due to close vicinity to major blood
vessels and nerves. VHL mutation–derived PHEOs/PGLs are almost
always adrenal, non-metastatic, but frequently bilateral and/or re-
current, thus adrenal sparing treatment options are of high importance
[3]. SDHA, SDHC, and SDHAF2 mutation–derived PHEOs/PGLs
are rare and have not yet been characterized in detail. Large cohort stud-
ies including PHEO/PGL patients revealed that SDHA, SDHC, and
SDHAF2 are extremely rare (0.1–0.5%, 0.4–2.2%, and non-detectable,
respectively) [9–13]. In a Dutch population of HN PGL patients,
SDHAF mutations were found in 4% and SDHC mutations in 0.4%
of cases (SDHA not tested) [14].
To date, genetic testing presents an important diagnostic tool for
risk assessment of PHEO/PGL patients and their families. However,
genetic testing is cost intensive and targeted therapeutic options for
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the distinct subtypes of PHEOs/PGLs are not yet available. Detec-
tion of novel therapeutic targets for the particular PHEO/PGL sub-
types mandates the identification of subtype-specific characteristics,
e.g., by gene expression profiling.
In the present study, gene expression profiles of pseudohypoxic
PHEOs/PGLs were compared among each other and to normal ad-
renal medulla (NAM) to identify new signatures for disease stratifi-
cation. The study was designed to decrease variability as much as
possible by using homogeneous sample groups of SDHB, SDHD,
and VHL mutation–derived PHEOs/PGLs as has been previously
recommended [15]. Due to limited access to an appropriate number
of samples, no SDHA, SDHC, and SDHAF2 mutation–derived
PHEOs/PGLs were included. Association of specific pathways or
genes with the distinct phenotypes of pseudohypoxic PHEOs/PGLs
may lead to identification of new diagnostic markers and potential
therapeutic targets.
Materials and Methods
Tissue
PHEO/PGL tissue was collected with informed consent at Dutch
and US centers: the National Institutes of Health (Bethesda, MD),
Tufts Medical Center (Boston, MA), Baylor College of Medicine
(Houston, TX), Radboud University Nijmegen Medical Centre
(Nijmegen, The Netherlands), and Erasmus MC (Rotterdam, The
Netherlands). NAMs were collected from anonymous tissue donors at
Tufts Medical Center and Comenius University (Bratislava, Slovakia)
after confirmed brain death or during radical nephrectomy. Tissues were
collected under a protocol that was approved by the Institutional
ReviewBoard of the respective institutions.Genetic testingwas performed
with informed consent, following established guidelines for testing [1].
Normal medulla and cortex from the same adrenals (n = 8) were
separated as previously described [16]. In total, snap-frozen tissue of
45 histopathologically confirmed PHEOs/PGLs was used. The sam-
ples were grouped according to genetic/syndromic background and
tumor location: SDHB (n = 18), SDHD-abdominal/thoracic (AT;
n = 6), SDHD-HN (n = 8), and VHL PGLs (n = 13). Patient infor-
mation is summarized in Table 1.
Microarray Processing
RNA extraction was performed as previously described [16]. RNA
quality and quantity was ensured using Bioanalyzer (Agilent Tech-
nologies, Inc, Santa Clara, CA) and NanoDrop (Thermo Scientific,
Wilmington, DE), respectively. Samples were processed following the
recommended Affymetrix protocol. Fragmented and labeled cDNA
was hybridized onto GeneChip Human Gene 1.0 ST Arrays (Affyme-
trix, Santa Clara, CA). Staining of biotinylated cDNA and scanning of
arrays were performed according to the manufacturer’s recommenda-
tions. All data are available at the GEO database (GSE 39716).
Bioinformatic Analysis
RawCEL files were imported intoExpressionConsole 1.0 (Affymetrix).
Only “core” probe sets were used to perform “gene-level” probe set sum-
marization, background subtraction, and quantile normalization using
the RMA option in the software. Data analysis was performed using
R packages from the Bioconductor project (http://www.bioconductor.
org) [17].
To avoid bias due to potential cortical contamination, genes with
at least two-fold greater expression in cortex than medulla were de-
termined cortex-specific and removed from the data sets, resulting in
31,202 transcripts. For each sample, a ratio of the expression profile
to the mean expression profile of normal medulla was computed.
Gene-wise Z -score normalization across all samples was applied to
adjust for technical variation [18]. Differential expression analysis
was performed using significance analysis of microarray (SAM)
[19] with two- or multiclass option. False discovery rates were esti-
mated with 1000-fold sample permutations and significant gene
changes were arbitrarily selected at ≤ .02. Hierarchical clustering,
principal component analysis, between-group analysis, Kyoto Ency-
clopedia of Genes and Genomes (KEGG) annotation, and overrep-
resentation analysis (P value cutoff, .05) were performed using the
R packages “stats,” “made4”- and “GSA.” Gene network analysis and
functional categorization was performed with Ingenuity Pathway
Analysis (IPA; www.ingenuity.com). Class prediction analysis using
prediction analysis for microarray (PAMR) [20] was done to identify
10-fold cross-validated gene expression predictors for the four sub-
types of PHEOs/PGLs.
Quantitative Real-Time Polymerase Chain Reaction
RNA from a subset of tissues as indicated (Table 1) was used to
generate cDNA (SuperScript III First-Strand Synthesis SuperMix;
Life Technologies, Grand Island, NY) according to the manufacturer’s
recommendations. The following TaqMan primer probe sets (Life
Technologies) were used: 18S: 4319413E, ABCC9: hs00245832_m1,
ALDH1A1: hs00946916_m1, ARP11: hs00218475_m1, C7:
hs00175109_m1, CARTPT: hs00182861_m1, CFH: hs00962373_m1,
CGNL1: hs00262671_m1, DNAH14: hs00376554_m1, EGLN3:
hs00222966_m1, elongation of very long chain fatty acid protein 7
(ELOVL7): hs00405150_m1, F13A1: hs00173388_m1, F8:
hs00252034_m1, FCGR1A : hs00174081_m1, FCGR1B :
hs00417598_m1, FGF11: hs00182803_m1, GABRA1: hs00168058_m1,
GPC3: hs00170471_m1, GYG2: hs00418496_m1, HOXC6:
hs00171690_m1, KCNN2: hs00222059_m1, LGR5: hs00173664_m1,
MPP6: hs00212785_m1, NEFM: hs00606024_m1, OLFML2B:
hs00295836_m1, PLTP: hs01067287_m1, RAB3B: hs01001137_m1,
RARRES2: hs00161209_g1, SCIN: hs00263961_m1, SLC18A1:
hs00161839_m1, SLC9A7 : hs00261601_m1, SUCNR1 :
hs00908230_m1, TFAP2C: hs00231476_m1, TFPI: hs00196731_m1,
TMEM130: hs00905715_m1, VSNL1: hs02386966_m1. Cycling
conditions were as previously described [16]. Relative expression to
18S and normal medulla was estimated by the ΔΔC t method. Concor-
dance between quantitative real-time polymerase chain reaction (qRT-
PCR) validation data and microarray data was tested using the
correlation of correlation index [21]. Statistical evaluation of expression
differences for each of the classifiers between the groups were analyzed
by analysis of variance (ANOVA)with Student-Neuman-Keuls post-hoc
analysis adjusted for multiple comparisons.
Results
Purity of Adrenal Medulla Tissue
Separating human adrenal medulla from cortex is challenging due
to a convoluted border and cortical cell islands within the medulla.
To determine and exclude genes of cortical origin from the medulla
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samples, we used a computational approach. Of the total transcripts
4.73% (1551/32,740) were associated with adrenal cortex (P < .0001;
Figure 1A). Gene set enrichment analyses for cortex and medulla
samples with KEGG pre-compiled gene modules were performed
[22]. Significant enrichment (at P ≤ .05) of steroid hormone, andro-
gen, and estrogen metabolism was evident for cortex, while tyrosine
metabolism and neuronal functions were associated with medulla
(Figure 1B).
Gene Expression Profiles Classify Mutation/Location Subtypes
Initial screening by SAM yielded a total of 7366 differentially
expressed transcripts. Principal component analysis of samples
grouped by mutation/location showed clear separation of VHL and
SDHD-HN from each other as well as from the partly overlapping
SDHB and SDHD-AT PGLs (Figure 2A). In agreement, unsuper-
vised average linkage hierarchical clustering of significant genes using
pairwise Pearson correlation revealed separation of the tumors into
Table 1. Patient Information.
Sample ID Chip ID Genetic Backgr. Sex Age at Surgery Age at First Presentation Age at Dgn. Loc. Status MA qRT-PCR
01M/01C PKh_03* dna m 61.0 dna dna dna dna x 01M1
02M/02C PKh_04* dna nk nk dna dna dna dna x 02M*
03M/03C PKh_05* dna f 53.0 dna dna dna dna x 03M*,†
04-1M/04-1C PKh_06* dna f 72.0 dna dna dna dna x 04-1M*
04-2M/04-2C PKh_07* dna f 72.0 dna dna dna dna x 04-2M*
05M/05C PKh_42* dna m 65.0 dna dna dna dna x
06M/06C PKh_43* dna m 56.0 dna dna dna dna x
07M/07C PKh_44* dna m 62.0 dna dna dna dna x
08B PKh_40 SDHB f 30.0 27 30 A Pr-NM x
09B PKh_10 SDHB m 28.5 12 29 E Met x
10B PKh_11 SDHB m 24.0 20 23 E Pr-M x
11B PKh_13 SDHB f 46.0 28 46 A Pr-NM x
12B PKh_18 SDHB f 9.0 8 9 E Mlt-NM x x
13B PKh_19 SDHBP m 22.8 15–16 22 E Pr-M x
14B PKh_20 SDHB m 26.6 8 9 E Met x x
15B PKh_21 SDHB m 38.2 37 38 E Pr-M x
16B PKh_22 SDHB f 45.6 41 42 E Mlt-NM x
17-1B PKh_27 SDHB f 36.0 32 33 E Met x x
17-2B PKh_28 SDHB f 36.2 32 33 E Met x
18B PKh_31 SDHB m 52.0 40 41 E Met x
19B PKh_32 SDHB m 12.0 13 13 E Pr-NM x
20B PKh_33 SDHB m 31.0 30 30 E Pr-NM x x
21B PKh_34 SDHB m 55.0 50 53 E Mlt-NM x x
22B PKh_36 SDHB m 35.0 no symptoms 34 E Mlt-NM x
23B PKh_38 SDHB f 34.8 10 18 E Met x
24B PKh_39 SDHB m 17.1 15 15 A Mlt-NM x
25D(HN) PKh_37 SDHD m 24.3 23 23 HN Pr-NM x
26D(HN) PKh_60 SDHD f 34.0 34 34 HN Bi-M x
27D(HN) PKh_01 SDHD f 49.3 28 28 HN Pr-NM x x
28D(HN) PKh_02 SDHD f 61.1 60 60 HN Pr-NM x
29D(AT) PKh_08 SDHD m 16.0 16 16 A Pr-NM x x
30D(AT) PKh_09 SDHD f 31.0 31 31 A Pr-NM x x
31-1D(AT) PKh_24 SDHD f 26.6 23 24 A Mlt-NM x
31-2D(HN) PKh_25 SDHD f 26.6 23 24 HN Mlt-NM x x
31-3D(HN) PKh_29 SDHD f 27.1 23 24 HN Mlt-NM x
32D(HN) PKh_58 SDHD m 48.0 48 48 HN Bi-NM x x
33D(AT) PKh_26 SDHD m 61.4 58 58 A Pr-NM x x
34D(HN) PKh_59 SDHD f 29.0 29 29 HN Mlt-NM x x
35-1D(AT) PKh_35 SDHD m 31.8 31 25 A Mlt-NM x x
35-2D(AT) PKh_41 SDHD m 32.6 31 25 E Mlt-NM x
36V PKh_57 VHL f 24.8 no symptoms 17 A Bi-NM x
37-1V PKh_55 VHL m 22.7 18 22 A Bi/Mlt-NM x
37-2V PKh_56 VHL m 23.1 18 22 A Bi/Mlt-NM x
38V PKh_54 VHL m 16.1 16 16 A Bi/Rec-NM x
39V PKh_53 VHL m 28.6 no symptoms <28 A Pr-NM x
40V PKh_52 VHL m 13.1 no symptoms 12 A Bi-NM x
41V PKh_45 VHL f 42.8 nk <41 A Pr-NM x
42V PKh_46 VHL m 29.4 29 29 A Bi/Mlt-NM x
43V PKh_47 VHL f 42.6 nk <15 A Bi-NM x x
44V PKh_48 VHL m 39.2 nk 39 A Pr-NM x x
45V PKh_49 VHL m 30.6 <30 30 A Bi-NM x
46V PKh_50 VHL m 33.1 4 5 A Bi/Mlt/Rec-NM x x
47V PKh_51 VHL m 18.9 no symptoms 16 A Bi/Mlt-NM x
48V dna VHL m 33.5 nk nk A Bi-NM x
A indicates adrenal; f, female; backgr., background; Bi, bilateral; dgn., diagnosis; dna, does not apply; E, extra-adrenal; ID, identifier; loc., location; m, male; M, metastatic; MA, microarray; met,
metastases; Mlt, multifocal primary; nk, not known; NM, non-metastatic; Pr, primary; Rec, recurrent; SDHDP, SDHD-polymorphism; x indicates sample used in experiment specified by column heading;
patients 25, 31, and 40 were first-degree relatives to 35, 33, and 47, respectively.
*Applies to normal medulla samples.
†Included for ACTR10, EGLN3, F8, LGR5, MPP6, NEFM, SLC18A1, TMEM130, and VSNL1.
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two main clusters (Figure 2B), cluster A consisting of SDHB and
SDHD-AT PGLs and cluster B containing VHL and SDHD-HN
PHEOs/PGLs. Cluster B is further divided into separate VHL and
SDHD-HN PHEO/PGL subclusters.
Supervised PAMR was used to narrow down the genes of interest
under maintenance of optimal classification capabilities. Ten-fold
cross-validation yielded 6937 transcripts with an overall misclassifica-
tion rate of 0.175 (Figure 2C and Table W1). SDHD-HN PGLs
were classified with high confidence (zero misclassifications). Sample
discrimination by cluster analysis based on the 6937 genes main-
tained the assignment into two major clusters (data not shown).
Enriched Functions in PAMR Analysis
To determine which functional themes corresponded to the gene
expression profiles of the two main clusters, we performed a series of
comparisons using IPA. Cluster A was associated with 425 and clus-
ter B with 1270 upregulated genes. Canonical pathway analysis by
IPA identified 17 and 121 significantly changed pathways (P < .05),
respectively (Table W2). Fourteen pathways (82%) selected for
cluster A were found to be involved in metabolism. The top cluster A
pathways included oxidative phosphorylation (OXPHOS), mito-
chondrial dysfunction, ubiquinone biosynthesis, and citrate cycle
(Table W2).
Figure 1. Proportion of cortical and medullary genes and their associated functions in normal control samples. (A) Venn diagram of the
two-fold differentially expressed probes identified in normal cortex with reference to normal medulla. For each subset of genes, a Pearson
correlation coefficient was calculated between the two sets of controls and shown within the parenthesis. (B) Heatmap of pathways
associated with normal cortex and normal medulla.
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In cluster B, 91 (75%) of the 121 significantly changed pathways
were found to be involved in hepatic fibrosis and immune function
(Table W2). Hierarchical clustering using the differentially expressed
genes from the top IPA functions, i.e., 14 OXPHOS (cluster A) and
44 hepatic fibrosis genes (cluster B), led to clear separation of PHEOs/
PGLs according to mutation/location (Figure 3A).
Differential Expression of Selected OXPHOS Genes
To elaborate the differences in OXPHOS complex expression, we
compared the shrunken centroid scores from the PAMR model be-
tween the PHEO/PGL subtypes (Figure 3B). Overall, expression of
OXPHOS genes appeared decreased in VHL, close to normal in
SDHD-HN, and increased in SDHD-AT and SDHB PHEOs/
PGLs. Seventeen and seven of 25 mitochondrial complex I genes were
above normal in SDHD-AT and SDHB PHEOs/PGLs, respectively,
while decreased expression prevailed in VHL PHEOs (22/25 genes).
Similarly, mitochondrial complex IV genes were below normal in
VHL (8/10) and above normal in SDHD-AT (8/10) and SDHB (2/10).
Patterns for the other complexes were analogous.
Differential Expression of Selected Hepatic Fibrosis Genes
Upregulated genes typically associated with tissue fibrosis from
cluster B (Table W2) included fibrillar collagens COL1A2 and
COL3A1, matrix metalloprotease 2 (MMP2), metalloprotease inhib-
itor A2M, the chemotactic protein CCL2, the contractile proteins
MYL9, growth factor signaling–related transcripts (IGF1, IGFBP4,
IGFBP5, CTGF/IGFBP8, VEGFC, FLT1/VEGFR1, FLT4/VEGFR3,
KDR/VEGFR2,PGF,PDGFA,PDGFRA,PDGFB,PDGFRB,HGF, and
EGFR), and the transcriptional regulator NFKB1, including several
players of nuclear factor κB (NFκB) activation (IL1RI, IL1RAP, IL1RL2,
EGFR, and TLR4). As mentioned above, 44 genes of the hepatic fibrosis
pathway have been identified to be upregulated in cluster B by enrich-
ment analysis, including several genes involved in NFκB signaling. For
this reason, wematched the list of 6937 genes fromPAMR to a published
list of NFκB target genes (source: http://bioinfo.lifl.fr/NF-KB/). In total,
53 genes from our PAMR data were identified as NFκB targets, most of
which were upregulated in cluster B tumors (Figure 3C).
Among others, activation of NFκB has been shown to induce
epithelial-to-mesenchymal transition (EMT). EMT markers have
been recognized as indicators of poor prognosis or aggressive behav-
ior and recent reports have proposed important EMT genes such as
TWIST1 and SNAI1 as markers of malignancy in PHEOs/PGLs
[23,24]. Thus, we performed a cluster analysis of our samples based
on a list of 92 EMT genes [24], 44 of which mapped to our SAM
list. Several key players in EMT (e.g., TWIST1, TCF3, and MMP1)
were not part of our SAM list, because a difference in expression
between the groups was not present or not sufficient to withstand per-
mutation analysis. On the basis of the heatmap of 44 EMT genes, we
found that up-regulation of certain EMT genes may play a role in some
metastatic SDHB tumors; however, the same EMT genes are elevated
Figure 2. Unsupervised analysis of tumors with SDHB, SDHD, and VHL mutations. (A) Group level principal component analysis showing
association of the different tumors. Projection lines from each group correspond to individual sample locations on the resulting axes.
(B) Heatmap of a pairwise correlation of genes from significance analysis for microarrays. Hierarchical cluster analysis was performed by
average linkage and correlation distance metrics. (C) Class prediction results of the nearest shrunken centroid model. Cross-validation
errors of the classifiers are shown as a function of the threshold parameter. The value giving minimum errors was chosen to give a selected
list of genes.
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in a number of non-metastatic samples and thus do not qualify as
stand-alone markers of malignancy in our sample set (Figures W2
and W3). Cluster analysis based on EMT genes essentially confirmed
the pattern described above, although group separation was not quite as
clear as when based on all SAM genes or OXPHOS and hepatic fibrosis
(Figure W3).
Minimum Subset of Classifiers
To identify the most characteristic genes for each of the PHEO/
PGL subtypes, we selected a minimum set of top 10 genes with
strongest group association for each of the mutation/location classes
from the PAMR data (including upregulated and downregulated
genes). The choice of this selection is heuristic and we found that
less than 10 genes from any class resulted in higher misclassifications
(data not shown). Surprisingly, the minimum subset of classifiers im-
proved classification capabilities compared to the 6937 PAMR-selected
genes (overall error rate: 0.066, SDHB: 0.05, SDHD-AT: 0.16,
SDHD-HNP: 0.00, VHL: 0.07). A heatmap (Figure 4A) and a profile
plot (Figure 4B) show relative expression scores of the 40 classifiers
(36 unique genes). To validate proper characterization and to poten-
tially identify stand-alone markers for each group, qRT-PCR for 35
of the 36 genes of interest was performed. Comparison between micro-
array and qRT-PCR data showed an overall correlation of correlation
coefficient of 0.87 (SDHB: 0.87, SDHD-AT: 0.97, SDHD-HN: 0.92,
VHL: 0.57). Thus, the qRT-PCR results essentially confirmed the
microarray data (Figure 5A).
Subgroup Classification Based on Individual Genes
Classification of cluster B tumors based on individual genes was
feasible for both subgroups. qRT-PCR confirmed discriminatory capac-
ity of 8/10 candidates for VHL PHEOs. Six of them were more highly
expressed in VHL (TFAP2C, EGLN3, GPC3, FGF11, CGNL1, and
F8), and two were least expressed in VHL PHEOs (LGR5 and
ELOVL7; Figure 6). Interestingly, the latter were significantly elevated
in all SDHx mutation–derived PHEOs/PGLs. In addition, one gene
predicted to characterize SDHB was most highly expressed in VHL
tumors (ABCC9). Thus, we identified nine genes that showed distinct
expression in VHL PHEOs from the other groups. Three of them also
qualified as classifiers for another tumor group (CGNL1 for SDHD-AT;
ABCC9 and FGF11 for SDHD-HN).
Significantly different expression in SDHD-HN PGLs compared
to all other groups was evident for seven of nine candidates. Two genes
showed increased (SUCNR1 and OLFML2B) and five genes showed
decreased expression (SLC18A1, NEFM, CARTPT, TMEM130, and
HOXC6) in SDHD-HN PGLs (Figure 6). As mentioned above,
FGF11 and ABCC9 levels also distinguished SDHD-HN PGLs from
all other groups. SCIN and CFH levels in SDHD-HN were signifi-
cantly different from the other PHEO/PGL subtypes. Thus, in total,
we identified 11 characteristic genes for SDHD-HN PGLs.
Identification of characteristic individual genes was less successful
for cluster A PHEOs/PGLs. While CGNL1, OLFML2B, GABRA1,
and KCNN2 expression of SDHD-AT PHEOs/PGLs was distinct
from that of all groups except normal medulla (Figure 6), expression
of none of the top ranked genes for SDHB was significantly different
Figure 3. Canonical pathways associated with the tumor subgroups. (A) Heatmap of oxidative phosphorylation and hepatic fibrosis-
related transcripts selected by IPA. (B) Mean expression score of oxidative phosphorylation complex subunits. (C) Mean expression
of NFκB target genes in the tumor subgroups. Red indicates increased and blue decreased expression relative to normal medulla and
the other PHEO/PGL subtypes.
Neoplasia Vol. 15, No. 4, 2013 Expression Profile of Pseudohypoxic Paragangliomas Shankavaram and Fliedner et al. 441
from SDHD-AT PHEOs/PGLs. However, DNAH14, C7, and
NEFM were significantly differentially expressed in SDHB PHEOs/
PGLs compared to NAMs, SDHD-HN PGLs, and VHL PHEOs
(Figure 6).
Expression levels of three evaluated genes were characteristic for
NAM (C7, F13A1, and DNAH14; Figure 6). In addition, DNAH14
clearly separated cluster A and B tumors. Graphs of additional tested
genes are depicted in Figure W1.
Discussion
Previous studies revealed divergent expression patterns in pseudo-
hypoxic PHEOs/PGLs, which allowed genotype discrimination [7–9].
Commonly, SDHx PHEOs/PGLs have been grouped together, pre-
venting detection of differences. Mining for disease-relevant character-
istics requires normalization to healthy tissue. Thus, we evaluated the
gene expression profiles of pseudohypoxic PHEOs/PGLs associated
with SDHB, SDHD, and VHL mutations in relation to NAM. Our
major new findings are that SDHD-HN PGLs are different from
SDHD-AT PGLs and more closely resemble VHL PHEOs. These
observations indicate that expression profiles of pseudohypoxic PHEOs/
PGLs depend on tumor location as well as underlying mutation.
Purity of Adrenal Medulla Tissue
Computational analysis determined the content of cortical genes
within the medulla samples at 4.73%. This agrees with our previous
study, where cortical contamination of the medulla samples was esti-
mated to be less than 5% [16]. Although this represents a reasonable
degree of purity, in “-omics” type studies ∼5% contamination may
cause significant bias. Thus, we excluded cortical genes from the
medulla data sets.
Mutation and Location Determine Expression Profiles
Unsupervised analysis revealed similarities in the expression pat-
terns of SDHB- with SDHD-AT PHEOs/PGLs and SDHD-HN
PGLs with VHL-derived PHEOs, respectively. This indicates that
SDHD-derived PHEOs/PGLs differ depending on the tissue of origin.
Remarkably, two SDHD-HN PGLs and one PHEO from the same
patient clearly separated into the different clusters.
In agreement with our findings, HN PGLs clustered in close vicin-
ity to VHL PHEOs upon unsupervised analysis in a previous study
involving sporadic and hereditary PHEOs/PGLs [8]. Contrary to our
results, no separation into distinct VHL PHEO and HN PGL sub-
clusters has been observed. The good separability of our sample set
may be due to the stringent sample selection criteria, i.e., well-defined,
homogenous subgroups of pseudohypoxic PHEOs/PGLs. The study of
Lopez-Jimenez et al. involved HN PGLs of different genetic back-
grounds (SDHB, SDHC, and SDHD mutations and apparently spo-
radic), which clustered in close proximity to each other but apart from
AT PGLs with underlying mutations in the same genes [8]. Consis-
tently, a different study reported that gene expression of HN PGLs
appeared uniform, independent of hereditary background (PGL1/
SDHD, PGL2/SDHAF2, or sporadic) [25]. Thus, mutational back-
ground appears to have less influence on the expression pattern of
PHEOs/PGLs than their location.
Figure 4. Minimum subset of classifiers for separation of the different mutation/location types. (A) Unsupervised hierarchical clustering
of the gene expression data of the minimum subset of 40 classifiers. The different tumor types (red, SDHB; blue, SDHD-HN; green,
SDHD-AT; cyan, VHL) are distinguished by the pattern of up-regulation (red) and down-regulation (blue). Separation into two main clus-
ters, a shared SDHB and SDHD-AT cluster and one that further subclusters into VHL and SDHD-HN PGLs, is evident. (B) Profile plot
depicting expression levels (shrunken centroid scores) for the minimum subset of classifiers, i.e., 10 top scoring genes for each class.
Bars facing right represent positive and those facing left represent negative shrunken centroid scores indicating increased and decreased
expression relative to normal medulla and the other PHEO/PGL subtypes.
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While distinct expression profiles in SDHD-HN and SDHD-AT
PHEOs/PGLs are unexpected because of mutual SDHD malfunc-
tion, prominent differences in their biochemical phenotypes are well
known. Only a subset of HN PGLs may secrete catecholamines
(29%) [26], while almost all AT PHEOs/PGLs are biochemically
active [27]. The distinct secretory characteristics probably reflect dif-
ferent cells of origin for sympathetic AT PHEOs/PGLs and parasym-
pathetic HN PGLs. Thus, despite the same genetic background,
differences in gene expression patterns seem plausible. However, par-
allels between sympathetic VHLPHEOs and parasympatheticHNPGLs
currently appear limited.
To our surprise, SDHD-AT and SDHB PHEOs/PGLs did not
separate into distinct subclusters. In addition, the different types of
SDHB samples involved did not cluster according to their character-
istics (metastases, primary metastatic, or primary non-metastatic).
Seven of nine SDHB-metastatic samples fell into cluster A. However,
the same cluster contained 14 non-metastatic SDHB and SDHD-AT
PHEOs/PGLs. Thus, we do not see an indication that the composition
of cluster A reflects aggressive or malignant potential of the included
PHEOs/PGLs. Despite involving 50% metastatic SDHB samples, no
gene signature of metastatic PHEOs/PGLs could be identified. Sub-
grouping SDHB samples into metastatic (n = 9, i.e., n = 6 metastases
and n = 3 primary metastatic) and primary non-metastatic (n = 9) gave
inacceptable error rates of 44.4% for SDHB–non-metastatic and 55.6%
for SDHB-metastatic (see TableW3).We thus concluded that the differ-
ences between SDHB-metastatic and SDHB–non-metastatic samples
were less pronounced than those to the other groups, possibly because only
a few genes discriminate SDHB-metastatic and SDHB–non-metastatic
samples. However, we cannot exclude that the poor classification was
based on the relatively small sample number for each of the subgroups
(n = 9 each). Since a very large proportion of SDHBPHEO/PGLpatients
develop metastases, and classification of SDHB tumors as non-metastatic
can only be based on the fact that metastases have not (yet) presented, we
decided to abstain from subgrouping of the SDHB samples.
Enriched Biologic Functions in Cluster A
Cluster A was associated withmetabolic pathways, such as OXPHOS,
mitochondrial dysfunction, ubiquinone biosynthesis, and citric acid
cycle. Disturbances in the mitochondrial energy metabolism are
anticipated in tumors with mutations in the mitochondrial SDH com-
plex. As enzyme of the citric acid cycle, SDH converts succinate into
fumarate. Simultaneously, electrons are donated to ubiquinone, an essen-
tial electron carrier of the OXPHOS. Here, we report a potentially com-
pensatory up-regulation of pathways that are directly connected to SDH
function in AT PGLs with underlying SDHB and SDHD mutations.
Differential Expression of Selected OXPHOS Genes
Up-regulation of OXPHOS transcripts was prevalent in SDHB
and SDHD-AT PGLs, supporting our previous finding of increased
expression of several OXPHOS subunits in SDHB compared to VHL
mutation–derived PHEOs/PGLs [28]. Which subunits were upregu-
lated was rarely mutual between both subgroups. Thus, SDHB and
SDHD mutations apparently both influence OXPHOS gene expres-
sion in AT PHEOs/PGLs but not SDHD-HN PGLs.
Favier et al. reported low expression of severalOXPHOS genes in SDHx
PHEOs/PGLs [7]. Discrepancy with our data may again be due to differ-
ences in sample selection. The SDHx group of Favier et al. contained HN
PGLs, which in our study did not show increased OXPHOS subunit
expression. Furthermore, SDHB, SDHC, and SDHD mutation–derived
PGLs were grouped together. The limited agreement in OXPHOS sub-
unit expression between SDHB, SDHD-AT, and SHD-HN PGLs men-
tioned above may have concealed their distinct expression profiles.
Decreased expression of OXPHOS subunits related to VHL muta-
tions has been previously reported and indicates decoupling of glycol-
ysis and OXPHOS [7,29].
Compensatory up-regulation to rescue an impaired energymetabolism
in consequence of SDHx dysfunction seems probable. However, the reg-
ulatory mechanism remains to be elaborated. Possibly up-regulation
occurs in a disconcerted manner, which may fail to enhance OXPHOS
capacity or even increase reactive oxygen species generation. Special atten-
tion should be given to the finding that despite underlying SDHDmuta-
tions, no up-regulation of OXPHOS genes was evident in HN PGLs.
Enriched Biologic Functions in Cluster B
In cluster B, hepatic fibrosis and immune functions were among
the top enriched pathways. Tissue fibrosis is excessive accumulation
of extracellular matrix (ECM) components, which is the physiologic
response to injury and is facilitated by inflammatory mediators. Tissue
Figure 5. Correlation heatmap of Pearson correlation results for
35 genes of the minimum subset of classifiers between micro-
array and qRT-PCR data. The mutation types are shown as colored
bars below the dendrograms (red, SDHB; blue, SDHD-HN, green,
SDHD-AT; cyan, VHL).
Neoplasia Vol. 15, No. 4, 2013 Expression Profile of Pseudohypoxic Paragangliomas Shankavaram and Fliedner et al. 443
Figure 6. Relative expression of selected genes of theminimum subset of 35 genes to NAM. The genes are arranged into clusters according
to their capabilities as classifiers (VHL vs. all, SDHD-HN vs. all, SDHD-AT vs. all, NAM vs. all). Overlapping indicates that the respective genes
show characteristic expression in two of the tumor groups. Overall significance has been evaluated for each gene by ANOVA (value given for
each gene in the upper left corner). Significant differences between each group and (a) NAM, (b) SDHB, (c) SDHD-AT, (d) SDHD-HN, and
(e) VHL are indicated above each applicable column. Replications of the letter specify the level of significance (xxx, P < .001; xx, P < .01;
x, P < .05).
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fibrosis and inflammation initiation have been shown to be direct or
HIF stabilization–dependent consequences of VHL mutations. In
hepatic cells, VHL mutations have reportedly caused fibrosis and pro-
moted inflammation in an HIF-2α–dependent manner [30]. Trans-
genic HIF-2α stabilization has also been shown to promote renal
fibrosis [31]. In addition, direct interaction of pVHL with the ECM
component collagen IV has been described [32,33]. VHL mutations
disrupt this interaction and cause improper collagen matrix assembly.
Faulty ECM assembly due to VHL mutations has been accompanied
by increased expression of MMP2 [34], which was also elevated in our
cluster B tumors (Figure 4C). Kurban et al. reported that inappropriate
ECM assembly in consequence of VHL mutations facilitates angio-
genesis, tumor development, and invasion. Thus, disrupted interaction
between VHL and ECM components appears to be a crucial HIF-
independent tumorigenic trait. Tissue fibrosis and inflammation genes
were overexpressed in VHL and, even more so, SDHD-HN PGLs. To
our knowledge, these pathways are currently entirely unexplored in
SDHD-HN PGLs. HIF-2α–mediated initiation of tissue fibrosis and
inflammation may be common to all pseudohypoxic PHEOs/PGLs.
Similar expression of HIF-2α in VHL- and SDHx-derived PHEOs/
PGLs [7] and predominance of HIF-1α in the latter have both been
observed [35]. In any case, the reason for normal expression of tissue
fibrosis and inflammation genes in SDHx-AT compared to SDHD-
HN and VHL PHEOs/PGLs remains to be determined.
Consideration of Selected Hepatic Fibrosis-Related Genes
The hepatic fibrosis pathway is interrelated with several other
pathways, including NFκB, vascular endothelial growth factor
(VEGF), platelet-derived growth factor (PDGF), and insulin-like
growth factor 1 (IGF1) signaling, which have been previously shown
to play a role in PHEOs/PGLs or other tumors.
For instance, VHL negatively regulates NFκB [36], and accord-
ingly, VHL mutations strengthen NFκB activity, which causes apop-
tosis resistance, increased angiogenesis, and therapy resistance in
renal cell carcinomas. Recently, inhibition of NFκB signaling in a
murine PHEO model has been shown to cause cell death and signifi-
cant decrease in metastatic spread [37]. Similarly, NFκB inhibition
showed promising results in treatment of renal cell carcinomas [38].
Our data indicate that particularly in cluster B PHEOs/PGLs targeting
the NFκB pathway provides a promising new therapeutic approach.
Pseudohypoxic PHEOs/PGLs often appear highly vascular, and
anti-angiogenic treatment has been suggested [39]. Induction of angio-
genic transcripts/VEGF signaling has been described in response to
NFκB as well as HIF activation. Here, we report increased expression
of VEGF signaling–related transcripts in cluster B tumors, i.e., VEGFC,
FLT1/VEGFR1, KDR/VEGFR2, and FLT4/VEGFR3. Increased
expression of VEGF, FLT1/VEGFR1, and KDR/VEGFR2 has been
previously reported for a group of PHEOs/PGLs, including one
VHL case [40]. While potentially all pseudohypoxic PHEOs/PGLs
show elevated expression of angiogenesis genes, the particular genes
mentioned here appear to be exclusively upregulated in VHL and
SDHD-HN PGLs. Thus, targeting VEGFR1, 2, and 3 in cluster B
PHEOs/PGLs appears to be a promising approach.
As an aspect of hepatic fibrosis, PDGF signaling showed several
elevated players in cluster B. PDGFB is a well-described oncogene
[41] and targeting PDGFRB and VEGF led to symptom relieve and
tumor shrinkage in a VHL patient with multiple tumors, including a
metastatic PGL [42]. Activating mutations in PDGFRA is often seen
in gastrointestinal stromal tumors.
IGF signaling has been previously shown to play a role in the patho-
genesis of PHEOs/PGLs. Here, we show elevated expression of
IGF1 and several binding proteins (IGFBP4, IGFBP5, and CTGF/
IGFBP8) in cluster B tumors. Fottner et al. have previously reported
increased expression of IGF1 receptor (IGFR1/FCGR1A) in human
PHEOs, including three VHL cases [43]. Inactivation of VHL has
been shown to cause increased IGFR1/FCGR1A expression [44],
which contributes to renal tumor development. Increased IGFR1/
FCGR1A levels have been associated with chemoresistance and
IGF1 signaling inhibition improved treatment outcome in renal cancer
[45]. Differences in IGFR1/FCGR1A expression between the two clus-
ters was not evident; however, IGFR1/FCGR1A was selected into the
minimum subset of classifiers for characterization of SDHB PHEOs/
PGLs. QRT-PCR revealed significantly elevated expression in SDHD-
HN compared to SDHD-AT PGLs (Figure W1). Expressions of IGF1
itself as well as several regulating IGF-binding proteins however were
elevated in cluster B tumors. Up-regulation of IGFBP4 in nine PHEOs
of unknown genetic background has been reported [46]. Fernandez
et al. observed that IGF1 signaling is crucial in cell proliferation and
tumor maintenance in a mouse model based on mouse PHEO cells
[47]. Further studies are mandated to explore the role of IGF signaling
in cluster B tumors and its potential value as a therapeutic target.
Minimum Subset of Genes to Characterize
PHEO/PGL Subtypes
Selected genes of the minimum subset will be discussed here for
their potential role in the distinct pseudohypoxic PHEOs/PGLs. In
agreement with previous reports, we detected increased EGLN3/
PHD2 transcript in VHL PHEOs compared to the other groups
[8,48]. EGLN3 protein level however did not differ between VHL
and SDHB PHEOs/PGLs [8]. Inhibition of EGLN3-mediated cul-
ling has been proposed as a common mechanism in PHEO/PGL
development [49]. Thus, despite its elevated mRNA expression in
VHL-derived PHEOs, EGLN3 function may be inhibited, either
due to JUNB-mediated inhibition or inadequate protein expression.
In addition to a role inmediating apoptosis, EGLN3/PHD2 also acts
asHIF PHD. Asmentioned above,VHLmutations can in appropriately
stabilize HIFα. As HIF target gene, particularly responding to HIF2α
stabilization, EGLN3 induction is thus not surprising in VHL-derived
tumors [50]. However, despite HIF stabilization EGLN3/PHD2 tran-
script levels appear normal in other pseudohypoxic PHEOs/PGLs [7,9].
Elevation of EGLN3/PHD2mRNA levels exclusively in VHL PHEOs/
PGLs further supports distinct manifestations of pseudohypoxia.
In further agreement with our data, differential expression between
VHL and SDHB PHEOs/PGLs has been previously reported for
RARRES2, CGNL1, and ELOVL7 [8].
Two genes that we found to be significantly decreased in SDHD-
HNPGLs compared to all other groups were SLC18A1, the chromaffin
granule amine transporter also known as VMAT1, and the intermediate
neurofilament NEFM (also called NFM, NF-M, or NF3). Previously,
varying levels of SLC18A1/VMAT1 expression have been reported for
PHEOs/PGLs [51,52]. In agreement with our data, SLC18A1/
VMAT1 has been previously shown to be more highly expressed in
VHL PHEOs than normal adrenal [53]. NEFM may be mandatory
in carotid body maturation under hypoxia [54] and has been proposed
as marker for neuroendocrine tumors [55].
In combination, the minimum subset of classifiers could not clearly
differentiate tumors within cluster A. Nevertheless, four individual
genes were characteristic for SDHD-AT relative to all other PHEOs/
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PGLs but not normal medulla. Overall, our findings indicate that the
differences in expression profiles of SDHB and SDHD-AT PHEOs/
PGLs are subtle and identification of distinguishing features may
require large analysis groups, perhaps homogenous to the level of par-
ticular mutation and/or location.
In disregard of their failure as characteristic genes for one partic-
ular subgroup, two candidate genes were more highly expressed in all
SDHx cases relative to adrenal medulla and VHL-derived PHEOs.
First, LGR5 (aliases: GPR49, HG38, FEX, and GPR67) has been rec-
ognized as stem cell marker in multiple adult tissues and cancer [56].
Its increased expression specifically in SDHB-derived PHEOs/PGLs
has been previously reported [9]. Contrarily, our data indicate simi-
larly elevated LGR5 levels in SDHB and SDHD PGLs (Figure 6).
Due to its cell surface location and potential role in tumor-initiating
stem cells, this receptor may provide an excellent therapeutic target
in SDHx PHEOs/PGLs. Second, the lipogenic ELOVL7 has been
reported to be involved in prostate cancer growth [57].
Summary
Pseudohypoxic PHEOs/PGLs can be stratified according to differ-
ent hereditary backgrounds and/or tumor locations. Surprisingly,
SDHD-AT and SDHD-HN PHEOs/PGLs do not cluster together
but with SDHB (cluster A) and VHL PHEOs/PGLs (cluster B), re-
spectively. Despite their distinct risks of malignancy, SDHB and
SDHD-AT PHEOs/PGLs failed to separate into distinct subclusters.
This indicates surprising agreement in their expression profiles and
prevented the identification of distinct gene signatures.
The majority of upregulated pathways were related to energy metab-
olism for cluster A and to tissue fibrosis and immune function for clus-
ter B. Overall, OXPHOS genes were more highly expressed in cluster A
tumors; however, which particular subunits were overexpressed differed
for SDHD-AT and SDHB PHEOs/PGLs. Cluster B tumors showed
increased tissue fibrosis, including NFκB-, PDGF-, IGF-, IL1-, and
VEGF-related gene expression.
Classification based on a minimum subset of 36 genes maintained sep-
arability of the groups into twomain clusters,with clusterB further dividing
into subclusters in agreementwith the respectivemutation types. Subgroup
classification based on the minimum subset of 36 genes improved error
rates. Expression levels of 35 genes from the minimum subset of classifiers
were essentially confirmed by qRT-PCR. Evaluation of the potential of
each of those genes to correctly classify the different subtypes of pseudo-
hypoxic PHEOs/PGLs identified expression of nine transcripts as charac-
teristic for VHL, 11 for SDHD-HN, and four for SDHD-AT PHEOs/
PGLs; however, none successfully classified SDHB PHEOs/PGLs.
In conclusion, pseudohypoxic PHEOs/PGLs show distinct expression
profiles, which should be taken into account for improvement of diagno-
sis as well as the development of customized therapeutic options. Special
consideration should be given to the apparently distinct manifestations
of SDHD mutations in sympathetic and parasympathetic tissues.
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Figure W1. Relative expression of 12 genes of the minimum subset of 35 genes to NAM, which did not confirm the expression pattern
predicted by the microarray. Overall significance has been evaluated for each gene by ANOVA (value given for each gene in the upper
left corner). Significant differences between each group and (a) NAM, (b) SDHB, (c) SDHD-AT, (d) SDHD-HN, and (e) VHL are indicated
above each applicable column. Replications of the letter specify the level of significance (xxx, P < .001; xx, P < .01; x, P < .05).
Figure W2. Unsupervised hierarchical clustering of EMT genes. Forty-four of 92 EMT genes provided by Loriot et al. [24] were signif-
icantly differentially expressed between the mutation/location types (P ≤ .05) and led to separation of the samples into two main clus-
ters. Color blocks above the heatmap indicate tumor behavior (top row) and mutation/location (bottom row). In the top row, brown and
red indicate non-metastatic and metastatic samples, respectively. The colors in the second row indicate the following: red, SDHB;
green, SDHD-AT; blue, SDHD-HN; cyan, VHL.
Figure W3. Boxplots of relative expression levels of selected EMT genes as determined by microarray of our sample set. Our sample set
does not reproduce the findings of Loriot et al., reporting decreased expression of CDH2 and KRT19 and increased expression of LOXL2,
TWIST1, MMP1, and MMP2 in SDHB-metastatic samples compared to all non-metastatic samples [24]. Differential expression of
TWIST1, TCF3, andMMP1 between the groups lacked statistical significance by SAM at a threshold P value of .05. This may be because
SDHB samples were not subgrouped into metastatic and non-metastatic previous to SAM. In agreement with Loriot et al., we did not
observe elevated SNAI1 and SNAI2mRNA expression in SDHB tumors. Nonetheless, the localization or level of the protein snail and slug
may differ between metastatic and non-metastatic PHEOs/PGLs as has been previously reported [23,24].
Table W3. Classification and Cross-Validated Misclassification Error Rates for the Shrunken
Centroid Model Including Subgrouping of SDHB Samples into Metastatic (n = 9) and Non-
Metastatic (n = 9).
SDHB–NM SDHB-M SDHD-AT SDHD-HN VHL Class
Error Rate
SDHB–NM 5 3 0 0 1 0.44
SDHB-M 3 4 0 1 1 0.56
SDHD-AT 1 0 5 0 0 0.17
SDHD-HN 0 0 0 8 0 0.00
VHL 0 0 1 2 10 0.23
Overall error rate 0.28
